Millennium reports 5.5% Unicycive stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Integrated Core Strategies (US) LLC, together with Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, reports beneficial ownership of 1,172,667 shares of Unicycive Therapeutics, Inc. common stock, representing 5.5% of the outstanding class as of 01/16/2026. The filing shows no sole voting or dispositive power, with all voting and disposal rights reported as shared among the reporting persons.
The shares are held through entities subject to voting control and investment discretion by Millennium Management LLC and other affiliated investment managers, with Millennium Group Management LLC as managing member and Mr. Englander as sole voting trustee of its managing member. The reporting parties state that the securities were not acquired and are not held for the purpose of changing or influencing control of Unicycive and are instead reported on a passive basis under Schedule 13G.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much of Unicycive Therapeutics (UNCY) stock does Millennium report owning?
Who are the reporting persons in this Unicycive Therapeutics (UNCY) Schedule 13G?
Is the Millennium stake in Unicycive Therapeutics (UNCY) reported as passive or activist?
What voting and dispositive powers do the reporting persons have over Unicycive Therapeutics (UNCY) shares?
What does the joint filing agreement in Exhibit I for Unicycive Therapeutics (UNCY) cover?
AI-generated analysis. How Rhea-AI works. Not financial advice.